S1PR2 signaling has been demonstrated to drive NASH (12, 64), while genetic S1PR3 ablation predisposes HFD-fed mice to inflammation/steatosis (65). This evidence concerns the gene S1PR3 and metabolic dysfunction-associated steatohepatitis.